Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Watson Pharma Buys Actavis in a Marriage of Generic Drugmakers

publication date: Apr 26, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Watson Pharmaceuticals of the US acquired privately held Actavis Group at a price of about $5.6 billion upfront, plus earn-out provisions based on 2012 results. Both companies are large generic drug manufacturers, and together they will constitute the third biggest generic drug company in the world. Although neither company has a huge presence in China – only about 2% of Watson’s revenues currently come from Asia – the acquisition will add to Watson’s presence in both China and India. More details....

Stock Symbol: (NYSE: WPI)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners